Breaking News
Sort by:
Top Post
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
ProBioGen, a Berlin-based specialist for developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines, and […]
Protai Adds $12 Million to Seed Round to Build an Oncology Drug Discovery Pipeline
Protai, a proteomics and AI-powered drug discovery startup revolutionizing the way new drugs are discovered, […]
DEM BioPharma Appoints Miriam Merad, M.D., Ph.D., to Scientific Advisory Board
DEM BioPharma, an immune-oncology company developing therapies that target signals on cancer cells and macrophages […]
Myosin Therapeutics Closes Seed Round to Continue Development of Innovative Therapies for Glioblastoma and Stimulant Use Disorder
Myosin Therapeutics, a biotechnology company leveraging its innovative platform technology to identify new molecular entities […]
Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies
Mediar Therapeutics, a biotechnology company advancing a portfolio of first-in-class therapies that halt and even […]
Cambrian Bio launches Amplifier Therapeutics to Develop Clinical-Stage AMPK Activator
Cambrian Bio, a clinical-stage biotechnology company focused on treating and preventing chronic diseases of aging, […]
Porton Advanced and Bennu Biotherapeutics Announced a Strategic Partnership to Accelerate Cell Therapy Development for Solid Tumors
Porton Advanced Solutions and Bennu Biotherapeutics have announced a strategic partnership to advance cell and […]
BIOCORP Signs With HRA Pharma for the Development of a Medical Device Innovation
BIOCORP, a French company specialized in the design, development, and manufacturing of innovative medical devices, […]
Teitur Trophics Raises €28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases
Teitur Trophics, a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative […]
VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan
VectivBio, a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, and Asahi […]
Ambrx Raises $78 Million and Completes its ATM Program
Ambrx Biopharma today announced that it has completed net sales of approximately $78 million of […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more